Navigation Links
Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting

eliver ARIAD's lead cancer product candidate to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.

This press release contains "forward-looking statements," including statements related to initiation of our Phase 3 clinical trial in metastatic sarcomas in the third quarter of 2007. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the conduct and results of pre-clinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market products resulting from our development efforts, our reliance on partners and other key parties for the successful development, manufacturing and commercialization of products, the adequacy of our capital resources and the availability of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceedings concerning our NF-(kappa)B patent portfolio, the potential acquisition of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned subsidiary, ARIAD Gene Therapeutics, Inc., future capital needs, key employees, markets, economic conditions, prices, reimbursement r
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:8/20/2014)... Transparency Market Research ... (MCA) Market for Cellulosics, Agrochemicals, Surfactants, Thioglycolic Acid (TGA) ... Growth, Trends and Forecast 2014 - 2020". The global ... in 2013 and is anticipated to reach USD 1,046.7 ... during the forecast period from 2014 to 2020. In ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces ... available in its catalogue: Wireless ... RFID, Zigbee, UWB WWAN, WMAN, WLAN and ... Kalorama Information,s Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ...
(Date:8/20/2014)... , Aug. 20, 2014   Ventana Medical ...  Group, today announced that its VENTANA System for ... in the European Union for routine pathology, including ... consisting of VENTANA Virtuoso software coupled with either ... HT slide scanner, provides automated digital slide creation, ...
Breaking Medicine Technology:Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3
... Week Dec. 2-8, HARRISBURG, Pa., Dec. 3 ... wants all children in,Pennsylvania to help stop spreading germs ... officials are celebrating National Hand Washing Awareness Week,Dec. 2-8, ... "Hand washing is one of the most important ...
... ALTO, Calif., Dec. 3 Telik, Inc.,(Nasdaq: TELK ... 1,dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets at the ... presentation is,scheduled for Saturday, December 8, 2007, from 5:30 ... Georgia World Congress Center in Atlanta. The presentation,(Abstract # ...
Cached Medicine Technology:Health Secretary Reminds Kids to Stop Germs - Wash Hands 2
(Date:8/20/2014)... Line: A study in Australia examined patient and ... (a marker of tumor cell growth) in an ... cancer in patients. , Author: ... Victoria, Australia, and colleagues. , Background: The ... cell division) has been connected with prognosis and ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 Hundreds ... on behalf of women who were allegedly injured due ... forward in New Jersey’s Bergen County Superior Court, Bernstein ... issued on August 15, 2014, the Court has established ... for Mirena lawsuits that are part of the proceeding’s ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... cells grow may help doctors diagnose and treat the most ... have found that the deadliest skin cancers occur most often ... long history of sun exposure. These lesions also grow ... cell growth -- called "high mitotic rate" -- is ...
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that nerves ... and that blocking nerve signals using surgery or Botox ... The study was conducted by the laboratory of Timothy ... PhD, in Norway and is published in today,s issue ... long observed that human and mouse cancers contain a ...
Breaking Medicine News(10 mins):Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... Schweitzer (Chair of the Democratic Governors Association) and Maryland ... applauded President Obama,s reported selection of former DGA Chair ... Services. "Our health care system is broken, and Governor ... effort to fix it," Governor Schweitzer said. "In reforming ...
... rare, orphan and neglected diseases, launches iWish, which allows people to ... diseases through and image. In addition, people are invited to explain ... solutions for a rare disease or for the community in general. ... ...
... research presented at the 2009 American Orthopaedic Society of ... elbow ulnar collateral ligament (UCL) reconstruction prior to selection ... increase the risk of future injury or affect the ... no statistical difference between athletes who had undergone UCL ...
... Communication Service introduces vSling for capturing and distributing ... Smile Reminder will highlight their newest practice-to-patient ... Society Midwinter Meeting. Attracting thousands of dental practitioners ... platform for Smile Reminder to show its revenue ...
... experts urge better awareness of how machines work , , ... clearing the sidewalk quicker and easier, but those who ... with hand injuries and accidental amputations, say medical experts. ... not the type of injuries that can be reconstructed," ...
... 27 LCA-Vision Inc. (Nasdaq: LCAV ) ... independent research and proxy advisory firm, today recommended that ... of Directors and reject all of the proposals, including ... replacement Directors, in the Joffe Group,s consent solicitation. ...
Cached Medicine News:Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 3Health News:Elbow ligament reconstruction appears not to effect future professional advancement in baseball 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 3Health News:Snowblower Hand Injuries Often Extensive, Study Finds 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 3Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: